Interleukin-2 and interferon alpha 2 combination

descriptionPublicationkeyboard_double_arrow_right Article 01 Nov 1996Publisher:Spandidos PublicationsJournal:Oncology Reports (issn: 1021-335X, eissn: 1791-2431,

Copyright policy )

Authors: P, Pronzato; A, Vigani; F, Vaira; F, Tani; M, Vanoli;

doi: 10.3892/or.3.6.1137

pmid: 21594525

Interleukin-2 and interferon alpha 2 combination

- Summary
- Metrics

Abstract

We have studied activity and toxicity of subcutaneous recombinant interleukin-2 and interferon alpha 2b in a series of 14 patients with advanced renal cell carcinoma. No objective response was observed, and the median survival was 16 months (range 3-19); toxicity was acceptable. All the patients had poor prognostic factors and were pretreated with interferon.

Impact byBIP!

	selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	0
	popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.	Average
	influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	Average
	impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.	Average